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In complex with the cosubstrate UDP-N-acetylglucosamine (UDP-GlcNAc), O-linked-GlcNAc transferase (OGT)
catalyzes Ser/Thr O-GlcNAcylation of many cellular proteins and proteolysis of the transcriptional coregulator
HCF-1. Such a dual glycosyltransferase–protease activity, which occurs in the same active site, is unprecedented and
integrates both reversible and irreversible forms of protein post-translational modification within one enzyme.
Although occurring within the same active site, we show here that glycosylation and proteolysis occur through
separable mechanisms. OGT consists of tetratricopeptide repeat (TPR) and catalytic domains, which, together with
UDP-GlcNAc, are required for both glycosylation and proteolysis. Nevertheless, a specific TPR domain contactwith
the HCF-1 substrate is critical for proteolysis but not Ser/Thr glycosylation. In contrast, key catalytic domain res-
idues and even a UDP-GlcNAc oxygen important for Ser/Thr glycosylation are irrelevant for proteolysis. Thus, from
a dual glycosyltransferase–protease, essentially single-activity enzymes can be engineered both in vitro and in vivo.
Curiously, whereas OGT-mediated HCF-1 proteolysis is limited to vertebrate species, invertebrateOGTs can cleave
human HCF-1. We present a model for the evolution of HCF-1 proteolysis by OGT.
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Most eukaryotic proteins undergo post-translationalmod-
ifications (PTMs), which diversify their function by regu-
lating protein activity, localization, and turnover, thereby
controlling diverse processes such as transcription, cell
signaling, nutrient sensing, DNA repair, and apoptosis
(Deribe et al. 2010; Hanover et al. 2012; Tessarz and Kou-
zarides 2014; Gambetta and Müller 2015). These PTMs
can be both reversible (e.g., phosphorylation, ubiquitina-
tion, and glycosylation) and essentially irreversible (e.g.,
proteolytic cleavage). The finding (Capotosti et al. 2011)
that the glycosyltransferase O-linked N-acetylglucos-
amine (O-GlcNAc) transferase (OGT) can both glycosy-
late cellular proteins and proteolytically cleave the
transcriptional coregulator HCF-1 has presented an un-
foreseen intersection between reversible and irreversible
protein modification.
O-GlcNAcylation involves the addition of GlcNAc to
substrate Ser/Thr residues of numerous nuclear and cyto-
plasmic proteins (Hart et al. 2011). This reversible modifi-
cation is achieved by a complex of OGT and the
cosubstrate UDP-GlcNAc. As UDP-GlcNAc is produced
by the nutrient-dependent hexosamine biosynthetic path-
way (Hart et al. 2011), it has been suggested that
O-GlcNAcylation by the OGT:UDP-GlcNAc complex
serves as a nutrient sensor to regulate such processes as
gene expression (see Dehennaut et al. 2014).
HumanOGT consists of two distinct similarly sized do-
mains: an N-terminal tetratricopeptide repeat (TPR)
domain and a trilobal C-terminal catalytic (Cat) domain
(Jinek et al. 2004; Lazarus et al. 2011). The TPR domain
contains 13.5 TPRs, each representing a 34-amino-acid se-
quence that folds into two anti-parallel α helices; the 13.5
TPRs assemble to form a superhelical spiral fold (Jinek
et al. 2004), a structure well suited to mediate protein–
protein interactions (Kreppel and Hart 1999; Iyer and
Hart 2003; Lazarus et al. 2013). The Cat domain contains
N-terminal (N-Cat) and C-terminal (C-Cat) domains (sep-
arated by an intervening Int-D domain) with apparently
different functions: The N-Cat domain contains residues
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implicated in catalysis, whereas the C-Cat domain pro-
vides binding sites for the sugar donor cosubstrate UDP-
GlcNAc and sugar acceptor substrate peptide (Lazarus
et al. 2011).
HCF-1 is an extensively O-GlcNAcylated transcrip-
tional coregulator that, serving as an “adaptor” protein,
links diverse DNA sequence-specific transcription factors
with numerous different chromatin-modifying proteins,
including OGT, and, as such, regulates mammalian cell
proliferation and metabolism (Wysocka et al. 2003;
Ruan et al. 2012; Zargar and Tyagi 2012). HCF-1 is pro-
duced as a large 2035-amino-acid precursor protein that
undergoes OGT-mediated proteolysis at six centrally lo-
cated, 26-amino-acid-long HCF-1 proteolytic (HCF-1PRO)
repeats (Capotosti et al. 2011) to generate heterodimers
of noncovalently associated N-terminal and C-terminal
subunits (Kristie et al. 1995; Wilson et al. 1995; Park
et al. 2012). OGT-mediated HCF-1 proteolysis is required
for proper HCF-1 cell cycle regulation (Capotosti et al.
2011).
OGT-mediated HCF-1 proteolysis occurs N-terminal of
a key glutamate residue at position 10 (E10) of the HCF-
1PRO repeat (in a C9–E10 sequence), creating a pyrogluta-
mate “cap” on the C-terminal cleavage fragment (Lazarus
et al. 2013). Cocrystallization of OGT and an HCF-1PRO
repeat revealed that the HCF-1PRO repeat mimics the
bindingmode of a glycosylation-competent peptide by po-
sitioning the critical E10 residue at the same site as occu-
pied by a serine glycosylation substrate (Lazarus et al.
2013). Indeed, an E-to-S substitution called E10S changes
the HCF-1PRO repeat from a proteolytic substrate into a
glycosylation substrate, indicating a very close relation-
ship between OGT-induced proteolysis and glycosylation
(Lazarus et al. 2013).
Here, we investigated the mechanism of OGT-induced
HCF-1 proteolysis by combining (1) computational mod-
eling and simulation, (2) mutational approaches, and (3)
chemical biology approaches. We show that, while at first
appearing very similar, glycosylation and HCF-1 proteoly-
sis are two distinguishable conserved activities of the
OGT:UDP-GlcNAc complex.
Results
A flexible linker separates the cleavage and threonine-
rich regions of the HCF-1PRO repeat
The sequences of the six HCF-1PRO repeats in human
HCF-1 are highly similar (Wilson et al. 1993; Kristie
et al. 1995). For historical and technical reasons and with-
out any evident differences, studies of HCF-1PRO repeat
proteolysis by OGT have combined structural studies of
OGT and HCF-1PRO repeat 2 (Lazarus et al. 2013) and pro-
teolysis studies ofOGTand principallyHCF-1PRO repeat 1
(Capotosti et al. 2011; Lazarus et al. 2013). Figure 1A
shows how these two HCF-1PRO repeats are nearly identi-
cal in sequence aswell as an illustration of the structure of
HCF-1PRO repeat 2 (yellow) bound to the OGT Cat (tan)
and TPR (blue) domains prepared by combining two sepa-
rate partial OGT crystal structures (Protein Data Bank
4N3B and 1W3B) (Jinek et al. 2004; Lazarus et al. 2011).
As noted, the HCF-1PRO repeat sequence has been subdi-
vided into cleavage (defined here as P7–E10) and threo-
nine-rich (T14–T24) regions (Capotosti et al. 2011).
Figure 1B shows how the cleavage region, which spans
the C9–E10 cleavage site, interacts with the Cat domain
and the UDP-GlcNAc cosubstrate (gray and turquoise
stick figures), whereas the threonine-rich region interacts
with many residues in the TPR domain (Lazarus et al.
2013).
Based on the OGT:UDP-GlcNAc:HCF-1PRO repeat 2
complex structure (Lazarus et al. 2013), we used molecu-
lar dynamics (MD) simulations to study the interactions
between the HCF-1PRO repeat cleavage and threonine-
rich regions and the OGT Cat and TPR domains. In these
simulations, we observed independent rigid body move-
ments of theOGTCat andTPR domains, as previously de-
scribed (Lazarus et al. 2011). The movements of the
cleavage region residues P7–E10 were strongly correlated
with theOGTCat domain (Fig. 1C, black circles), whereas
themovements of the threonine-rich region residues T14–
T22 were strongly correlated with the OGT TPR domain
(Fig. 1C, red squares). HCF-1PRO repeat residue E13, which
lies between the cleavage and threonine-rich regions and
at the interface of the Cat and TPR domains (see Fig. 1A,
B), represents the crossover point between the observed
Cat and TPR domain-associated movements.
MD simulation-derived thermal fluctuations of the
backbone and side chains of OGT-boundHCF-1PRO repeat
2 are displayed in Figure 1D. Whereas the HCF-1PRO re-
peat 2 backbone generally showed small fluctuations
(∼1.0 Å root mean square fluctuation [RMSF] for residues
P7–E10 and T14–T19) (Fig. 1D, black circles), the side
chains of residues T11, H12, and E13 showed significantly
higher side chain fluctuations (∼1.5 Å RMSF) (Fig. 1D, red
squares). These data are illustrated by themolecular repre-
sentation in Figure 1D, where the atom size and color
(small and blue represent rigid, and large and red represent
flexible) reflect RMSF values. Together with the afore-
mentioned backbone correlation data, these results sug-
gest that a T11–H12–E13 “linker” sequence (see Fig. 1A)
represents a flexible hinge between the cleavage and thre-
onine-rich regions of theHCF-1PRO repeat, allowing an op-
timal interaction with the positionally flexible Cat and
TPR domains of OGT (see also Supplemental Fig. 1A).
To probe side by side the roles of side chain function and
linker flexibility in HCF-1PRO repeat cleavage experimen-
tally, we investigated mutations of H12 and E13 in the
previously described cleavage substrateHCF-1rep1 (Capo-
tosti et al. 2011). Figure 1E shows the effects of mutations
to alanine (H12A and E13A) to probe side chain function
or to proline (individually H12P and E13P and in combina-
tion H12P/E13P) to restrict backbone movements and
thus probe in part the role of flexibility. These mutations
had no evident deleterious effect on HCF-1rep1 glycosyl-
ation (Supplemental Fig. 1B) or HCF-1PRO repeat binding
(Supplemental Fig. 1C). The alanine substitutions of
H12 and E13 also had no evident effect on HCF-1PRO re-
peat cleavage (Fig. 1E, cf. lanes 2, 4, 10, and 12), but the
proline substitutions significantly inhibited cleavage
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(Fig. 1E, cf. lanes 2, 6, 10, 14, and 16). Although H12P
and, to a lesser extent, E13P are predicted to have some
structural impact on the OGT-bound HCF-1PRO repeat
(data not shown), these results are consistent with the
“THE” linker sequence playing a flexibility as opposed
to a side chain specificity role for proteolysis. These re-
sults support the hypothesis that the “THE” linker resi-
dues adapt the cleavage and threonine-rich regions of
the HCF-1PRO repeat to the motions of the OGT Cat and
TPR domains.
TPR motif requirements for OGT proteolysis of HCF-1
Next,weanalyzed separately the functionof theOGTTPR
domain–HCF-1PRO repeat threonine-rich region unit and
the OGT Cat domain–HCF-1PRO repeat cleavage region
unit for glycosylation and HCF-1PRO repeat cleavage by
mutational analysis. With respect to the OGT TPR
domain, the cocrystal structure of the HCF-1PRO repeat
with OGT illustrated for the first time inmolecular detail
howtheTPRdomain, in this caseTPRs10–13.5, canhavea
Figure 1. TheHCF-1PRO repeat contains a conserved flexible linker. (A) HCF-1PRO repeat 2 (yellow) is shown bound to the TPR (blue) and
Cat (tan) domains of full-length OGT. Sequences of highly conserved HCF-1PRO repeats 1 and 2 are shown with the cleavage, linker, and
threonine-rich regions indicated.Residues 5–24ofHCF-1PRO repeat 2, observed in the crystal structure andused in themolecular dynamics
(MD) simulations, are highlighted in yellow,while the critical cleavage site residue E10 ismarked in red. (B) Depiction of HCF-1PRO repeat
2 andOGTbased on crystal structure 4N3B. TheHCF-1PRO repeat cleavage region (P7–E10) contacts the cosubstrateUDP-GlcNAc (shown
in stick representation; [gray]UDP; [turquoise]GlcNAc) in theCat domain (tan), whereas the threonine-rich region (T14–T24) contacts the
OGTTPRdomain (blue).We replaced theHCF-1PRO repeatQ10 residue in the catalytically inactive crystal structure byE10 (red arrow) and
replacedUDP-5S-GlcNAcbyUDP-GlcNAc. (C )MDsimulations identify correlations betweenHCF-1PRO repeat 2 (residues 6–22) cleavage
and threonine-rich region movements with UDP-GlcNAc-bound OGTCat and TPR domains, respectively. The root mean square devia-
tion (RMSD) of the HCF-1 backbonewith respect to the Cat domain is depicted as black circles, while the RMSDwith respect to the TPR
domain is depicted as red squares. (D) Root mean square fluctuations (RMSFs) of the HCF-1PRO repeat 2 (residues 6–22) bound to OGT.
(Black circles) Backbone only; (red squares) backbone and side chains. (Inset) Structural representation of RMSFs illustrated by atom
size and color (rigid is indicated by blue and small; flexible is indicated by red and large). (E) The HCF-1rep1 substrate (wild type [WT]
or mutant) was assayed with or without OGT for in vitro HCF-1 cleavage activity. HCF-1rep1 cleavage was detected using anti-GST an-
tibody, and OGT was detected using anti-T7 antibody. (Black bar) Uncleaved HCF-1rep1 substrate; (black circle) cleaved product.
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direct role in substrate binding and recognition (Lazarus
et al. 2013). We therefore probed here, by deletion of TPR
motif pairs, theoverall role of theOGTTPRdomain inpro-
teolysis and glycosylation as shown in Figure 2. We first
identified the minimal number of Cat domain-proximal
OGT TPR motifs that is required for effective glycosyla-
tion andHCF-1PRO repeat 1 cleavage by assaying the corre-
sponding activities of a set of progressive N-terminal TPR
motif pair deletion mutants. We used the HCF-1rep1 pro-
tein as a simultaneous glycosylation and cleavage sub-
strate and used the well-described nuclear pore protein
Nup62 substrate to assay glycosylation separately from
cleavage (Lazarus et al. 2005, 2006), as shown in Figure
2A (see the deletion schematic in Supplemental Fig. 2A).
Deletion of up to six N-terminal TPR motifs in Δ1–2,
Δ1–4, and Δ1–6 had no evident effect on either glycosyla-
tion or proteolysis of HCF-1rep1 (Fig. 2A, lanes 2–5);
thus, the 7.5 Cat domain-proximal TPRs (TPRs 7–13.5) re-
tain full glycosylation andHCF-1 proteolytic activities. In
contrast, Δ1–8 and Δ1–10 exhibited a progressive loss of
HCF-1rep1 and, to a lesser extent, Nup62 glycosylation
activity (Fig. 2A, lanes 6,7), which was accompanied by
a progressive increase in OGT autoglycosylation (see
Supplemental Fig. 2A; Lubas and Hanover 2000; Clarke
et al. 2008). In comparison, the Δ1–8 and Δ1–10 mutant
OGTmolecules weremuch less active for HCF-1rep1 pro-
teolysis (Fig. 2A, lanes 6,7), suggesting a more significant
role of OGT TPR motifs in HCF-1PRO repeat cleavage
than standard substrate glycosylation.
As the HCF-1PRO repeat threonine-rich region makes
multiple backbone and side chain contacts with Cat
domain-proximal TPRs (Lazarus et al. 2013), we asked—
by thecreationof internalΔ5–6,Δ7–8, andΔ9–10TPRdele-
tionmutants—whetherOGTTPR pairs play specific roles
inHCF-1 proteolysis. As shown in Figure 2B, internal dele-
tionofTPRpairs 5–6and7–8had little effect onHCF-1rep1
or Nup62 glycosylation (lanes 2–4), whereas deletion of
TPR pair 9–10 debilitated glycosylation of both substrates
(lane 5) and activated OGT autoglycosylation (see
SupplementalFig. 2B, lane5). (Wenote that theΔ9–10dele-
tion debilitatedNup62 glycosylationmore than theΔ1–10
deletion [Fig. 2, cf. A, lane 7, and B, lane 5], suggesting that
the remaining 1–8TPRs in theΔ9–10 deletion have a dom-
inant inhibitory effect in this mutant.) In comparison, the
TPR pair deletion series had a more pronounced effect on
HCF-1PRO repeat proteolysis, as, albeit the Δ5–6 TPR dele-
tionmutantwas fully active, both theΔ7–8andΔ9–10TPR
deletions displayed little if any HCF-1rep1 cleavage activ-
ity (Fig. 2B, lanes 3–5). The activity of the Δ5–6 TPR dele-
tion mutant is consistent with the activity of the Δ1–6
TPR deletion. The inactivity of the Δ7–8 and Δ9–10 TPR
deletionmutants suggests that theTPRs7–10play specific
functional or overall structural roles for HCF-1rep1 cleav-
age. Consistent with this possibility, as illustrated in
Supplemental Figure 2C, OGT TPR pairs differ consider-
ably at multiple structurally exposed residues. Whichever
thecase, however,with both sets ofTPRdeletionmutants,
HCF-1 proteolysis ismore sensitive toOGTTPRdeletions
than is glycosylation of two different substrates.
TPRmutations at the TPR–Cat domain interface disrupt
HCF-1PRO repeat cleavage without affecting Ser/Thr
glycosyltransferase activity
To extend the analysis of the OGT TPR domain to those
TPRs in the vicinity of the Cat domain, we took a point
mutational approach. The HCF-1PRO repeat threonine-
rich region contacts five conserved asparagine residues
of OGT TPRs 10–13.5, and simultaneous substitution of
these asparagine residues for alanine (see Fig. 3A, labeled
5N-5A) disrupts HCF-1PRO repeat–OGT interaction (Laza-
rus et al. 2013). The first threonine-rich region residue,
T14 (see Fig. 1A), makes the first contacts with the OGT
TPRs as the HCF-1PRO repeat passes from the Cat domain
to the TPR domain (Fig. 1B); there, it makes highly favor-
able peptide backbone contacts with the side chain of TPR
Figure 2. TPR domain requirements for HCF-1 proteolysis. (A)
Mutant OGTs containing progressive N-terminal TPR deletions
(schematic representation shown in Supplemental Fig. 2A) were
incubated with HCF-1rep1 or Nup62 and assayed for in vitro
HCF-1rep1 cleavage and glycosylation or Nup62 glycosylation
as described in the Materials and Methods. HCF-1rep1 cleavage
was detected with anti-GST antibody, whereas anti-O-GlcNAc
RL2 was used to detect HCF-1rep1 and Nup62 glycosylation.
Anti-T7 tag antibody was used to detect OGT. (B) Mutant
OGTs containing internal deletions of two TPR motifs at a
time (schematic representation shown in Supplemental Fig. 2B)
were incubatedwithHCF-1rep1 orNup62 and assayed for in vitro
HCF-1rep1 cleavage and glycosylation or Nup62 glycosylation as
described in A. The asterisk identifies a contaminating back-
ground band described in the Supplemental Material. (Black
bar) Uncleaved HCF-1rep1 substrate; (black circle) cleaved prod-
uct; (white bar) glycosylated uncleaved HCF-1rep1 substrate;
(white circle) glycosylated cleaved product.
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12 residue K396 and peptide backbone and side chain con-
tacts with the side chain of TPR 13 residue D431 (Fig. 3A;
Lazarus et al. 2013; Bhuiyan et al. 2015). Consistent with
these contacts, T14 is important for HCF-1PRO repeat
cleavage (Wilson et al. 1995; Capotosti et al. 2011;
Bhuiyan et al. 2015).
To probe further the importance of OGT TPR residues
for both glycosylation andHCF-1rep1 cleavage, wemutat-
ed three OGT side chains in the vicinity of T14 (see Fig.
3A)—the previously mentioned K396 and D431 residues
and K430, which does not contact the HCF-1PRO repeat
—and compared their activities with both wild-type
OGT and the glycosylation-defective (Clarke et al. 2008)
and proteolysis-defective (Lazarus et al. 2013) K842M
OGT point mutant. All three OGTTPR point mutants re-
tained HCF-1rep1 (Fig. 3B, HCF-1rep1 O-GlcNAc panel,
lanes 2–5) and Nup62 (Fig. 3B bottom panel, lanes 2–5;
see also Supplemental Fig. 3A) glycosyltransferase activi-
ty. (Note that the reducedNup62 glycosylation activity of
the D431Amutant observed in Figure 3B was exceptional
to the assay shown and not reproducible.) In contrast, in
the HCF-1rep1 cleavage assay, the three mutants were de-
bilitated for cleavage activity, with the K396A mutant
particularly so (Fig. 3B, top panel, lanes 3–5). The very
weak K396A mutant cleavage activity was striking, and
we therefore analyzed this mutant further.
First, we compared its relative HCF-1PRO repeat cleav-
age and Nup62 glycosylation activity in time-course as-
says, as shown in Figure 3C (see Supplemental Fig. 3C,D
for the primary data). These time courses revealed that
theK396AOGTmutant possesseswild-typeNup62glyco-
syltransferase activity (Fig. 3C left; see also casein kinase 2
[CK2] glycosylation in Supplemental Fig. 4A) but severely
reduced (∼50-fold) HCF-1PRO repeat cleavage activity (Fig.
3C, right). Thus, K396AOGT is an active glycosyltransfer-
ase with drastically reduced HCF-1PRO repeat activity.
One reason for the absence of K396AOGTHCF-1 cleav-
age activity could be due to a loss of affinity for the HCF-
Figure 3. TPR domain point mutations at the TPR–Cat domain interface selectively impact HCF-1 proteolysis. (A, top) Domain repre-
sentation of OGT: The positions of the five conserved asparagine residues replaced with alanines in the 5N-5Amutant (below) as well as
residues K396 andD431 (above) are shown. Structural representation: HCF-1PRO repeat 2 residue T14 interactionswithK396 (TPR 12) and
D431 (TPR 13) of the OGTTPRs. The OGTTPR domain and its residues are shown in blue, and the HCF-1PRO repeat is shown as a yellow
ball and stick representation. Interactions between T14 and OGT TPR residues are illustrated as black dashed lines. (B) HCF-1rep1 or
Nup62 was incubated with wild-type or mutant OGTs and assayed for in vitro HCF-1 proteolysis and glycosylation or Nup62 glycosyl-
ation. HCF-1rep1 cleavagewas detectedwith the anti-GST antibody, whereas HCF-1rep1 andNup62 glycosylation was detected with the
anti-O-GlcNAc RL2 antibody. Anti-OGT was used to detect OGT protein. (C ) Graph depicting the Nup62 glycosylation (left) and HCF-
1rep1 cleavage (right) activities ofwild-typeOGTandK396AOGT (Supplemental Fig. 3C,D). Glycosylation and cleavage efficiencieswere
calculated as described in theMaterials andMethods. n = 3, ±SD. (D) HCF3R-SEEwas incubatedwithwild-type, K396A, and K842MOGT
to assay cleavage (top panel) and glycosylation (middle panel). Anti-O-GlcNAc RL2 antibody was used to detect HCF3R-SEE glycosyla-
tion, and anti-His and anti-OGT antibodies were used to detect total HCF3R-SEE and OGT protein, respectively. (Black bar) Uncleaved
HCF-1rep1 substrate; (black circle) cleaved product; (white bar) glycosylated uncleaved HCF-1rep1 substrate; (white circle) glycosylated
cleaved product.
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1rep1 substrate, especially that the complementary HCF-
1PRO repeat T14A mutant substrate displays decreased
OGT affinity (Bhuiyan et al. 2015). However, an in vitro
binding assay showed that the K396A OGT mutant pos-
sesses good, albeit not wild-type, levels of HCF-1rep1-
binding affinity—indeed, better affinity than the 5N-5A
TPR mutant (Fig. 3A; Supplemental Fig. 3B, lanes 2–4);
thus, the absence of K396A OGT proteolytic activity is
not simply owing to a lack of affinity for the HCF-1PRO
repeat.
To compare directly the proteolysis-specific defect ver-
sus glycosylation activity of the K396A OGT mutant, we
took advantage of the previously described single E10S
HCF-1PRO repeat amino acid exchange mutant by which
(albeit artificially) the HCF-1PRO repeat is converted
from an OGT proteolysis substrate into a nearly identical
Ser glycosyltransferase substrate (Lazarus et al. 2013).
To use this approach, we prepared a construct related to
a previously described HCF3R construct, which contains
HCF-1PRO repeats 1–3 and thus is cleaved at three sites by
OGTbut serendipitously is not glycosylated byOGT (Laz-
arus et al. 2013). In our related construct called HCF3R-
SEE, the HCF-1PRO repeat 1 carries the E10S O-GlcNAc
acceptormutation. Using HCF3R-SEE, as shown in Figure
3D, the K396AOGTmutant again displays veryweak pro-
teolytic activity (top panel, cf. lanes 2–4) but, in the same
reaction, robust E10S glycosylation activity, as evidenced
by the effective O-GlcNAc labeling of the remaining
uncleaved HCF3R-SEE precursor (middle panel, cf. lanes
2–4). Thus, the K396A substitution creates an OGT en-
zyme that is defective for proteolysis but not glycosyla-
tion at two sites that differ by only a single amino acid
at the site of cleavage/glycosylation.
Cat domain mutations can disrupt Ser/Thr
glycosyltransferase activity without affecting HCF-1PRO
repeat cleavage
The above-mentioned studies illustrate how a bifunc-
tional wild-type OGT capable of glycosylation and prote-
olysis can be converted (via mutation of the TPR domain)
into a largely single-activity enzyme—in this case, readily
active for Ser/Thr glycosylation but not HCF-1PRO repeat
proteolysis. By mutating the Cat domain, we show here
how the opposite enzymatic preference can be achieved.
To date, manipulations of the UDP-GlcNAc cosub-
strate and OGTC-Cat domain have shown parallel effects
on glycosylation and HCF-1PRO repeat cleavage. Thus, for
both activities, UDP-GlcNAc is required (Capotosti et al.
2011; Lazarus et al. 2013), and the UDP-GlcNAc analog
UDP-5S-GlcNAc (Gloster et al. 2011) is not active (Laza-
rus et al. 2013). Additionally, C-Cat domain mutations
that block glycosylation also block HCF-1PRO repeat
cleavage (Capotosti et al. 2011; Lazarus et al. 2013). These
findings suggest thatOGTprotein glycosylation andHCF-
1PRO repeat cleavage are closely related enzymatic activi-
ties. Consistent with these observations, as mentioned
previously, the HCF-1 cleavage region mimics a glycosyl-
ation substratewhen it binds to OGT (Lazarus et al. 2013).
To probe the relationship between glycosylation and
HCF-1PRO repeat cleavage further, we assayed two series
of Cat domain mutants (shown in Fig. 4A): one series in-
volving residues K842 (Clarke et al. 2008; Martinez-
Fleites et al. 2008), K898 (Clarke et al. 2008), and H901
(Lazarus et al. 2011) in the UDP-GlcNAc and substrate
peptide-binding C-Cat domain (Lazarus et al. 2011) and a
second series involving residues S553, D554 (Lazarus
et al. 2005), and H558 (Martinez-Fleites et al. 2008; Laza-
rus et al. 2011) in the N-Cat domain critical for Ser/Thr
substrate O-GlcNAcylation.
We first assayed the effect of thesemutations onNup62
substrate glycosylation. The three individual mutations
within the C-Cat domain (K842M, K898A, and H901A)
abrogated OGT Nup62 glycosylation activity (Fig. 4B,
lanes 9–12). In the N-Cat domain, whereas the S553A
OGTmutant had no apparent effect Fig. 4B, (lane 3), single
alanine substitution of either of the neighboring D554 or
H558 residues reduced Nup62 glycosylation activity
(Fig. 4B, lanes 4,5), with the combined alanine substitu-
tions (D554A_H558A) having a more severe effect (Fig.
4B, lane 6). Similar effects were observed for HCF-1rep1
glycosylation (Fig. 4C, middle panels).
The three glycosylation-defective C-Cat domain muta-
tions were also defective for HCF-1PRO repeat cleavage
(Fig. 4C, top panel, lanes 9–12). In contrast, the N-Cat
domain D554, H558, and D554A_H558A glycosylation-
debilitated mutants retained wild-type HCF-1PRO repeat
cleavage activity (Fig. 4C, lanes 4–6); indeed, the D554A
mutation in isolation or in combination with the H558A
mutation enhanced HCF-1PRO repeat cleavage. These re-
sults indicate that these latter residues are more impor-
tant for Ser/Thr glycosylation than proteolysis.
This observation is strikingly reinforced by the activity
of a mutation in which the D554 and H558 side chains
have been exchanged in a so-called D554H_H558D
“swap” mutant. Here, the D554H_H558D swap mutant
did not display either Nup62 (Fig. 4B, lane 7; see also
Supplemental Fig. 4A for CK2 glycosylation) or HCF-
1rep1 glycosylation activity but did display full HCF-
1PRO repeat cleavage activity (Fig. 4C, lane 7). Consistent
with the wild-type level of proteolytic activity, MD simu-
lations failed to predict any effect of the D554H_H558D
swap mutant on the global structure of OGT or on the
binding of the HCF-1PRO repeat (Supplemental Fig. 4B).
These results show that, in contrast to the TPR domain
mutations, OGT N-Cat domain mutations can strongly
reduce Ser/Thr glycosyltransferase activity (see also
Bhuiyan et al. 2015) without evidently affecting HCF-
1PRO repeat cleavage activity. Additional OGT Cat
domain mutants, which showed either no inhibition of
HCF-1rep1 proteolytic and glycosylation activity or a con-
comitant decrease of both activities, are described in
Supplemental Figure 4C.
HCF-1 proteolysis is independent of the UDP-GlcNAc
α-phosphate oxygen-based Ser/Thr glycosylation
mechanism
Schimpl et al. (2012) proposed that the α-phosphate of the
UDP-GlcNAc plays a direct role in OGT-mediated
HCF-1 proteolysis by glycosylation-defective OGT
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substrate O-GlcNAcylation by activating the acceptor
site Ser/Thr side chain. Using diastereomers of αS-UDP-
GlcNAc in which either one or the other nonbonded α-
phosphate oxygen atoms (pro-S [Sp] and pro-R [Rp]) is
uniquely replaced with a sulfur atom, they showed that
only the Sp-αS-UDP-GlcNAc diastereomer, where the ox-
ygen faces the acceptor Ser/Thr residue, is functional for
glycosylation. Here, we asked whether the same αS-
UDP-GlcNAc diastereomer selectivity would be observed
in HCF-1PRO repeat cleavage.
Consistent with prior experiments, which used Tab1 as
substrate (Schimpl et al. 2012), the Sp-αS-UDP-GlcNAc
diastereomer but not the Rp-αS-UDP-GlcNAc diaster-
eomer was functional for both Nup62 (Fig. 5A, cf. lanes
4 and 6) and HCF-1rep1 (Fig. 5B, middle panel, lanes 4,6)
glycosylation by OGT. In stark contrast, both αS-UDP-
GlcNAc-diastereomers were functional for HCF-1PRO
repeat cleavage (Fig. 5B, top panel, lanes 4,6). This differ-
ential requirement for the UDP-GlcNAc α-phosphate Rp
oxygen for Ser/Thr glycosylation and HCF-1PRO repeat
cleavage shows that UDP-GlcNAc is used differently for
Ser/Thr glycosylation and proteolysis. Together with the
selective proteolytic activity of the D554H_H558D swap
mutant described above, these results show that both
components of the OGT:UDP-GlcNAc complex are dif-
ferentially involved in Ser/Thr glycosylation and HCF-
1PRO repeat cleavage.
The above-mentioned results indicate that the require-
ments for the OGT Cat domain and UDP-GlcNAc in
HCF-1PRO repeat cleavage are less stringent than for Ser/
Thr glycosylation. The unexpected activity of the OGT:
Rp-αS-UDP-GlcNAc complex for HCF-1PRO repeat cleav-
age led us to ask whether UDP-GlcNAc is used during
the HCF-1PRO repeat cleavage reaction when the Rp-αS-
UDP-GlcNAc diastereomer is used by assaying UDP re-
lease using a recently developed UDP sensor compound
(see the Materials and Methods; Borodkin et al. 2014).
Figure 5C shows that the wild-type HCF-1rep1 cleavage
substrate (E10) generated UDP in the presence of the Rp-
αS-UDP-GlcNAc diastereomer considerably more effec-
tively than the noncleavable HCF-1rep1 E10Q point
mutant. Thus, the Rp oxygen is not required for HCF-
1PRO repeat cleavage, but UDP-GlcNAc is still consumed
during the cleavage reaction.
Altered Ser/Thr glycosylation and HCF-1PRO repeat
cleavage activities are reproduced in an in vivo assay
The above-mentioned studies have revealed that the in vi-
tro Ser/Thr glycosyltransferase and HCF-1PRO repeat
Figure 4. A glycosylation-defective OGT is effective
for HCF-1 proteolysis. (A) Close-up view of the HCF-
1PRO repeat 2 cleavage region (yellow), with E10 (la-
beled in red) interacting with the UDP-GlcNAc-
bound (gray–turquoise) OGT Cat domain (tan). N-
Cat domain residues S553, D554, and H558 are la-
beled in black, whereas C-Cat domain residues
K842, K898, and H901 that interact with the UDP-
GlcNAc molecule are labeled in blue. (B) OGT N-
Cat (lanes 3–7) and C-Cat (lanes 10–12) domain mu-
tants were incubated with Nup62 to assay glycosyla-
tion activities. Anti-O-GlcNAc RL2 antibody was
used to detect Nup62 glycosylation, whereas anti-
OGT and anti-Nup62 antibodies were used to detect
OGT and Nup62 protein levels, respectively. (C )
HCF-1rep1 substrate was incubated with either
wild-type or OGT N-Cat (lanes 3–7) or C-Cat (lanes
10–12) domain mutants for in vitro HCF-1rep1 cleav-
age and glycosylation assay. HCF-1rep1 cleavage and
glycosylation were detected with anti-GST and anti-
O-GlcNAc RL2 antibodies, respectively. Anti-OGT
was used to detect OGT protein. (Black bar)
UncleavedHCF-1rep1 substrate; (black circle) cleaved
product; (white bar) glycosylated uncleaved HCF-
1rep1 substrate; (white circle) glycosylated cleaved
product.
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cleavage activities of OGT can be effectively separated by
pointmutation.We asked herewhether these selective ef-
fects are maintained in an in vivo environment, as we
imagined, for example, that cellular chaperones or other
OGT-associated proteins might maintain lost in vitro ac-
tivities and/or modify altered activities of selectively ac-
tive mutant OGT molecules. For this purpose, we
developed an in vivo assay by which the activity of ectop-
ically synthesized wild-type and mutant OGT molecules
can be assayed for both Ser/Thr glycosylation of endoge-
nous proteins and cleavage of a cosynthesized HCF-
1rep1 substrate as shown in Figure 6.
Ectopic synthesis of HCF-1rep1 molecules in HEK293
cells results in partial cleavage owing to the activity of en-
dogenous OGT (Bhuiyan et al. 2015). To establish our as-
say,we showed that coectopic synthesis of wild-typeOGT
(Fig. 6, Flag-OGT andOGT panels, lane 3) results in an en-
hanced cleavage of a cosynthesized HCF-1rep1 substrate
(Fig. 6, top panel, cf. lanes 2 and 3) and an enhanced glyco-
sylation of endogenous proteins (Fig. 6,O-GlcNAc panel,
cf. lanes 2 and 3). We note that with enhanced HCF-1rep1
cleavage, there is also a shift in the mobility of the
uncleaved and cleaved molecules; we suggest that this
mobility shift is due to increased glycosylation of HCF-
1rep1 molecules by the elevated levels of wild-type
OGT. Consistent with such an interpretation, overexpres-
sion of the inactive K842MOGTmutant did not affect ei-
ther HCF-1rep1 proteolysis or endogenous protein
glycosylation and did not induce an HCF-1rep1 fragment
mobility shift (Fig. 6, lane 6).
Figure 5. HCF-1 cleavage occurs independently of an α-phos-
phate-based mechanism. (A) Nup62 glycosylation with (lanes
1,3,5) or without (lanes 2,4,6) wild-type OGT and either UDP-
GlcNAc (lanes 1,2), Sp-αS-UDP-GlcNAc (lanes 3,4), or Rp-αS-
UDP-GlcNAc (lanes 5,6). Nup62 glycosylation was detected
using anti-O-GlcNAc RL2 antibody. Anti-Nup62 and anti-OGT
antibodies were used to detect Nup62 and OGT proteins, respec-
tively. (B) HCF-1rep1 cleavage assay with (lanes 1,3,5) or without
(lanes 2,4,6) wild-type OGT and either UDP-GlcNAc (lanes 1,2),
Sp-αS-UDP-GlcNAc (lanes 3,4), or Rp-αS-UDP-GlcNAc (lanes
5,6). HCF-1rep1 cleavage and glycosylation were detected using
anti-GST and anti-O-GlcNAc RL2 antibodies, respectively.
Anti-OGT antibody was used to detect OGT protein levels. (C )
UDP released as a by-product of HCF-1rep1 cleavage assays
with Rp-αS-UDP-GlcNAc with wild-type or uncleavable E10Q
HCF-1rep1 substrates was detected fluorimetrically, as described
in the Materials and Methods. n = 3, ±SD. (Black bar) Uncleaved
HCF-1rep1 substrate; (black circle) cleaved product; (white bar)
glycosylated uncleavedHCF-1rep1 substrate; (white circle) glyco-
sylated cleaved product.
Figure 6. In vivo glycosylation and HCF-1rep1 cleavage proper-
ties of activity-selective OGT mutants. HEK293 cells were
untransfected (lane 1), transfectedwithHA-GST–HCF-1rep1 vec-
tor alone (lane 2), cotransfected with wild-type (lane 3) or mutant
(lanes 4–6) Flag-OGT expression vectors as described in theMate-
rials andMethods. (Top panel) HA-GST–HCF-1rep1 cleavagewas
detected using anti-HA antibody and quantified as described
in the Materials and Methods. Endogenous HEK293 protein
O-GlcNAcylation was visualized with anti-O-GlcNAc RL2 anti-
body. Levels of ectopic recombinant Flag-OGT were detected
alone or in combination with endogenous OGT with anti-Flag
or anti-OGT antibody, respectively. (Bottom panel) An anti-actin
blot is shown as a loading control. To quantitate O-GlcNAcyla-
tion of endogenous proteins, the total combined intensity of
O-GlcNAcylated proteins in the untransfected HEK29 cells was
assigned an arbitrary value of 1. The relative intensities of
O-GlcNAcylation in each transfected sample were then calculat-
ed as a ratio between its combined protein O-GlcNAcylation in-
tensity over that of the untransfected lysate. The quantitation
indicated is for the experiment shown. Similar results were ob-
tained in three additional separate experiments.
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Reflective of their in vitro activities, in vivo, the Ser/
Thr glycosylation-competent K396A OGT mutant failed
to enhance HCF-1rep1 cleavage but did enhance glycosyl-
ation of endogenous proteins and induce an HCF-1rep1
fragment mobility shift (Fig. 6, lane 4), and the proteoly-
sis-competent swap OGT mutant enhanced HCF-1rep1
cleavage but not glycosylation of endogenous proteins
and did not induce an HCF-1rep1-fragment mobility shift.
Thus, the selective Ser/Thr glycosylation and proteolytic
activities of the K396A and swap OGT mutants observed
in vitro are retained in an in vivo environment.
We note with interest that, in the assay of the swap
OGT mutant, the glycosylation status of none of the en-
dogenous proteins was evidently enhanced using two dif-
ferent O-GlcNAc antibodies (see Supplemental Fig. 5).
This result suggests that the Ser/Thr glycosylation defect
of the swap OGT mutant is not substrate-specific.
The ability to cleave the HCF-1PRO repeat is conserved in
invertebrate OGT molecules
OGT glycosylation activity is conserved among both ver-
tebrates and invertebrates (seeOGT sequence comparison
in Supplemental Fig. 6; Hanover et al. 2005; Gambetta
et al. 2009; Sinclair et al. 2009; Selvan et al. 2015). HCF-
1 is also conserved, but, as shown for humans and fish
in Figure 7A, the HCF-1PRO repeat is present in HCF-1
only among vertebrate species. In contrast, in some inver-
tebrate species (e.g., Drosophila), the HCF-1 homolog is
still cleaved but by a different protease called Taspase 1
(Capotosti et al. 2007). Thus, HCF-1 proteolysis occurs
in both vertebrates and invertebrates, but only in verte-
brates is the unusual ability of OGT to cleave the HCF-
1PRO repeat used for HCF-1 cleavage. This observation
raises the question: Did vertebrate OGTs evolve to cleave
the HCF-1PRO repeat, or, instead, did the HCF-1PRO repeat
evolve to be cleaved generally by OGTs?
To address this question, we tested the ability of two
invertebrate OGT proteins—that of Drosophila mela-
nogaster, where HCF-1 is cleaved by Taspase 1 (Capotosti
et al. 2007), and that ofTrichoplax adhaerens (Selvan et al.
2015), where HCF-1 lacks an evident proteolytic cleavage
site (see Fig. 7A)—to cleave the HCF-1PRO repeat. Indeed,
as shown in Figure 7B, bothD.melanogasterOGT (lane 3)
and T. adhaeransOGT (lane 4) were active for HCF-1rep1
glycosylation and cleavage (see the black dots), with D.
melanogaster OGT being more active than T. adhaerans
OGT. Although less active, the veracity of T. adhaerans
OGT cleavage of the HCF-1PRO repeat was supported by
the finding that a T. adhaerans OGT K815M mutation
corresponding to the Ser/Thr glycosylation and HCF-
1PRO repeat cleavage-defective human OGT K842M mu-
tation (see Fig. 3) was also defective for HCF-1PRO repeat
cleavage (Fig. 3, cf. lanes 4 and 5). Consistent with con-
served invertebrate HCF-1 cleavage activity, residues
that are involved in HCF-1 proteolysis are conserved in in-
vertebrate OGT homologs (Supplemental Fig. 6). Of par-
ticular interest here is the residue K396 because we
show that, while important for proteolysis, it is not neces-
sary for Ser/Thr glycosylation and yet is conserved.Never-
theless, apparently, OGT did not evolve to cleave the
HCF-1PRO repeat, but rather the HCF-1PRO repeat evolved
to be cleaved by OGT.
Discussion
In this study, we separated the requirements forO-linked
Ser/Thr glycosylation and site-specific HCF-1PRO repeat
cleavage by the glycosyltransferase–protease OGT, thus
engineering, from a bifunctional enzyme, monofunc-
tional OGT:UDP-GlcNAc complexes fully active for
only O-linked Ser/Thr glycosylation or HCF-1PRO repeat
proteolysis in vitro or in vivo. The domains responsible
for supporting monofunctionality differed: Mutations in
theOGTTPR domain could affectHCF-1PRO repeat cleav-
agewithout affecting Ser/Thr glycosylation (see Figs. 2, 3),
and either (1) mutations in the OGT Cat domain or (2)
chemical alterations of UDP-GlcNAc could affect Ser/
Thr glycosylation without affecting HCF-1PRO repeat
cleavage (see Figs. 4, 5). As discussed below, we suggest
(1) that the OGTTPR domain ismore critical for position-
ing the HCF-1PRO repeat for cleavage than it is for
Figure 7. Invertebrate OGTs are active for HCF-1PRO repeat
cleavage. (A) Human (Homo sapiens [Hs]) HCF-1 and its homo-
logs found in other vertebrate (fish Takifugu rubripres [Tr]) and
invertebrate (Drosophila melanogaster [Dm] and Trichoplax
adhaerens [Ta]) species are shown. The twovertebrateHCF-1 pro-
teins contain HCF-1PRO repeats (yellow triangles), which are cod-
ed by single large exons (black bar). (Red filled triangle) Taspase 1
cleavage site; (red outlined triangle) degenerate Taspase 1 cleav-
age site; (Fn3) fibronectin type 3; (NLS) nuclear localization sig-
nal. (B) HCF-1rep1 cleavage assay was performed using human
(lanes 2,6), wild-type and K815M mutant Trichoplax (lanes 3,4,
respectively), and Drosophila (lane 7) OGTs as described in the
Materials and Methods. HCF-1rep1 cleavage and glycosylation
were detected using anti-GST and anti-O-GlcNAc RL2 antibod-
ies, respectively. Anti-his tag antibody was used to detect OGT
protein levels. (Black bar) Uncleaved HCF-1rep1 substrate; (black
circle) cleaved product; (white bar) glycosylated uncleaved HCF-
1rep1 substrate; (white circle) glycosylated cleaved product.
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positioningmany Ser/Thr glycosylation substrates and (2)
that the OGT Cat domain and UDP-GlcNAc are more
critical for Ser/Thr glycosylation than for HCF-1PRO re-
peat cleavage.
The HCF-1PRO repeat threonine-rich region makes nu-
merous intimate contacts within the OGT TPR domain,
whereas the HCF-1PRO repeat cleavage region interacts
with the OGT Cat domain and UDP-GlcNAc cosubstrate
(Lazarus et al. 2013). OGTMDsimulations have previous-
ly indicated largemovements of the TPR andCat domains
around a TPR 12–13 hinge (Lazarus et al. 2011). Here,
intimate HCF-1PRO repeat andOGT interactions are high-
lighted by the tightly coupled movements of the HCF-
1PRO repeat threonine-rich region with the OGT TPR
domain and the HCF-1PRO repeat cleavage region with
the OGT Cat domain. As revealed by MD simulations
and mutational analyses (see Fig. 1), these intimate
HCF-1PRO repeat–OGT interactions are aided by a novel
“flexibility” role of the small three-amino-acid “THE”
linker region, which adapts the HCF-1PRO repeat to the
bipartite OGT movements, promoting HCF-1 peptide
backbone flexibility that is important for its efficient
cleavage.
Previous studies have shown that mutant OGTs con-
taining truncations of its N-terminal TPR domain are still
active for peptide glycosylation (Iyer and Hart 2003). The
TPR domain deletion analysis presented here suggests
that OGT’s Ser/Thr glycosylation activity is less sensitive
to progressive N-terminal deletion than its HCF-1PRO re-
peat cleavage activity (see Fig. 2). Indeed, fully 6.5–7.5 Cat
domain-proximal TPR motifs are critical for efficient
HCF-1PRO repeat cleavage but not substrate glycosyla-
tion. Interestingly, the HCF-1PRO repeat is the only
OGT substrate thus far crystallized that shows intimate
binding with the extended OGT TPR domain (Lazarus
et al. 2013); other OGT glycosylation substrates only ex-
tend until the TPR–Cat domain interface (Lazarus et al.
2011; Pathak et al. 2015). Within the Cat-proximal 7.5
TPR motifs, there are stringent TPR motif sequence re-
quirements for HCF-1PRO repeat cleavage, as, for example,
HCF-1PRO repeat cleavage but not Ser/Thr glycosylation
is sensitive to internal deletion of TPRs 7 and 8 in this re-
gion. Consistent with these findings is the special nature
of the K396A mutation in TPR 12, which generates
a Ser/Thr glycosyltransferase-competent but proteo-
lysis-defective enzyme. The ability of the K396A OGT
mutant to bind but not cleave the HCF-1PRO repeat sub-
strate suggests that, in addition to binding the substrate,
the TPR domain plays a specific role in HCF-1PRO repeat
cleavage; we suggest that this role is in correctly “posi-
tioning” the HCF-1PRO repeat cleavage region in the Cat
domain for cleavage. This function could be critical, as
the key E10 glutamate for proteolysis specifically inhibits
HCF-1PRO repeat binding to the Cat domain (Bhuiyan
et al. 2015).
Within the OGT C-Cat domain responsible for UDP-
GlcNAc binding, deleterious mutations affect both Ser/
Thr glycosylation and HCF-1PRO repeat cleavage (see
Fig. 4; Supplemental Fig. 4; Capotosti et al. 2011; Laza-
rus et al. 2013; this study), suggesting that the binding
and positioning of UDP-GlcNAc in the Cat domain are
critical for both activities. In contrast, N-Cat domain
mutations can reduce Ser/Thr glycosylation activity
(Lazarus et al. 2013) without, as shown here, affecting
proteolysis. Here, we further identified the so-called N-
Cat domain D554H_H558D swap mutant, which dra-
matically impairs Ser/Thr glycosylation without having
any evident adverse effect on proteolysis. This distinc-
tion between glycosylation and proteolysis is now ex-
tended by the activities of the Rp-αS-UDP-GlcNAc-
bound OGT, which likewise, while failing to glycosylate
Nup62 or other proteins, is still fully active for HCF-
1PRO repeat cleavage.
Thus, with respect to both components of the OGT:
UDP-GlcNAc complex, we observed effective HCF-1PRO
repeat cleavage by glycosylation-incompetent enzyme:
cosubstrate complexes. A model has suggested that
HCF-1 proteolysis is initiated through a glycosylation-
like mechanism that involves formation of an unusual
glutamyl-ester between the E10 residue of the HCF-1PRO
repeat and the sugar molecule of UDP-GlcNAc (Lazarus
et al. 2013). Indeed, using amodel enzyme systemunrelat-
ed to OGT:GlcNAc glycosylation, Kötzler and Withers
(2016) have recently shown that glutamate glycosylation
is sufficient to induce an autolysis of the peptide bond be-
tween the glutamic acid and the preceding residue, gener-
ating an N-terminal pyroglutamate on the C-terminal
cleavage product (Kötzler and Withers 2016). If such a
mechanism is also true for HCF-1PRO repeat cleavage,
our results here—in which even the Ser/Thr glycosyla-
tion-incompetent OGT:UDP-GlcNAc complexes are ac-
tive for HCF-1PRO repeat cleavage—suggest that such
glutamate glycosylation is mechanistically distinct from
Ser/Thr glycosylation. We hypothesize that this distinc-
tion lies in the nature of the critical acidic side chain of
the E10 residue by which the carboxylate side chain group
is positioned close to the sugar component of UDP-
GlcNAc in the OGTCat domain (Lazarus et al. 2013). Un-
like for Ser/Thr glycosylation, this E10 residue probably
does not require assisted deprotonation (for example, trig-
gered by the nonbonded Rp oxygen of the UDP-GlcNAc α-
phosphate) to activate the attack on the anomeric carbon
of the UDP-GlcNAc sugar. The lack of such a preactiva-
tion step would explain why an OGT:UDP-GlcNAc com-
plex incompetent for Ser/Thr glycosylation can still
perform HCF-1PRO repeat cleavage.
How did OGT cleavage of HCF-1 arise?
HCF-1 proteolytic processing by OGT is unusual in the
nature of both the cleavage signal, a large highly con-
served HCF-1PRO repeat sequence, and the enzyme re-
sponsible for cleavage (an enzyme otherwise only
known to be involved in Ser/Thr glycosylation of intracel-
lular proteins). Without knowledge of the enzyme respon-
sible for HCF-1PRO repeat cleavage, it was suggested that
theHCF-1PRO repeats appeared inHCF-1 proteins through
a genetic recombination event, perhaps transposition, in a
vertebrate progenitor (Capotosti et al. 2007). The sugges-
tion was based on three observations: (1) As mentioned
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previously, only vertebrate HCF-1 proteins possess HCF-
1PRO repeats. (2) The HCF-1PRO repeat sequence is highly
conserved among and within vertebrate HCF-1 proteins
but cannot be found even in degenerate forms elsewhere
in vertebrate or nonvertebrate genomes. (3) As shown in
Figure 7A, the multiple HCF-1PRO repeat cleavage sites
within individual HCF-1 proteins are generally encoded
by one large exon as if they all appeared suddenly in an an-
cestral prevertebrate genome. We hypothesize here that,
prior to its acquisition in an ancestral prevertebrate
HCF-1-encoding gene by recombination, the HCF-1PRO
repeat sequence evolved in an ancient virus to serve as
proteolytic processing sites for viral maturation.
We base this hypothesis on two observations. First, the
sudden and highly conserved appearance of the HCF-1PRO
repeat sequence without any other related cellular se-
quence argues for an independent noncellular evolu-
tion of the HCF-1PRO repeat sequence. Second, viruses
often manipulate host cell machineries to their own
end. With the knowledge that proteolytic maturation is
a common feature of virus infectious cycles, we suggest
here that an ancestral virus engineered a protein sequence
(the HCF-1PRO repeat) to manipulate the OGT:UDP-
GlcNAc complex into promoting its own proteolytic
maturation.
In principle, given the ability of a glycosylated gluta-
mate residue to induce proteolysis (Kötzler and Withers
2016), a virus could have evolved the ability to be cleaved
by OGT if it could create an appropriate OGT-binding site
that positioned the key E10 glutamate to form a glycosyl-
ester due to glycosylation. The HCF-1PRO repeat exhibits
both of these properties: First, it is tightly bound by OGT
through the TPR domain, which, as shown here, is specif-
ically an important feature of HCF-1PRO repeat cleavage.
In contrast, the HCF-1PRO repeat cleavage region is not
particularly favorable for HCF-1PRO repeat binding to
OGT, as the E10 residue hinders OGT binding, a strain
that has been suggested to promote proteolysis (Bhuiyan
et al. 2015). Second, as shown by an MD simulation
(Supplemental Movie 1), the E10 residue is favorably posi-
tioned to induce an attack on the anomeric carbon of the
UDP-GlcNAc sugar. However a virusmay have evolved to
be proteolytically cleaved by OGT, it would have targeted
aspects of OGT function that are conserved even in organ-
isms in which HCF-1PRO repeat cleavage does not occur,
as both Trichoplax and Drosophila OGTs can cleave the
HCF-1PRO repeat.
Development of a mechanism for proteolytic matura-
tion via a glycosyltransferase whose activity is linked to
the metabolic status of the cell could have been favorable
for a virus, as it could permit the virus to coordinate its in-
fectious cyclewith cellmetabolic status.Wenote that, be-
fore OGT cleavage of HCF-1 in vertebrate species evolved,
HCF-1 cleavage was probably assured by Taspase 1
because vertebrate HCF-1 proteins retain vestigial non-
functional Taspase 1 cleavage sites, as shown in Figure
7; a sudden acquisition of HCF-1PRO repeats in the HCF-
1 protein in vertebrates could have permitted an improved
coordination of cell proliferation regulation with cell
metabolism.
Materials and methods
Antibodies
Antibodies were purchased as follows: anti-GST 1-109 (sc-33613),
anti-OGT (sc-32921), anti-CK2α (sc-12738), and anti-Nup62 (sc-
48373) from Santa Cruz Biotechnology; anti-O-GlcNAc RL2
from Abcam; anti-T7 and anti-S tags from Novagen.; anti-Flag
(F1804), anti-Actin, anti-O-GlcNAc (CTD110.6), and anti-His
(H1029) from Sigma-Aldrich; and anti-HA (3F10) from Roche Ap-
plied Science.
Bacterial and mammalian expression plasmids and
recombinant protein purification
Creation of plasmids and DNA templates used in this study are
described in the Supplemental Material along with the procedure
for synthesis and purification of recombinant proteins from bac-
terial cells.
In vitro HCF-1 cleavage and glycosylation assay
HCF-1rep1 cleavage and glycosylation Purified HCF-1rep1 (2.5
μM) was incubated in the presence of 500–1000 nM OGT (unless
otherwise noted) in 15 μL of TBS buffer (50mMTris at pH 7.4, 150
mM NaCl) supplemented with 1 mM UDP-GlcNAc (Sigma-Al-
drich, U4375) and 1mMDTT. The in vitro cleavage assay was in-
cubated for 8 h at 37°C, after which the reactionwas ended by the
addition of 2× Laemmli buffer and sample boiling. Anti-GST and
anti-O-GlcNAc RL2 antibodies were used to detect cleavage and
glycosylation of HCF-1rep1, respectively. Anti-T7 and anti-OGT
antibodies were used to determine levels of OGT.
HCF3R-SEE cleavage and glycosylation HCF3R-SEE cleavage
and glycosylation assay was performed by mixing 30 μM
HCF3R-SEE and 2.0 μM OGT (wild type or mutant) in 30 μL of
TBS buffer supplemented with 0.1 U/μL calf alkaline phospha-
tase, 1 mM UPD-GlcNAc, and 1 mM DTT for 4 h at 37°C. The
reactionwas ended by the addition of 2× Laemmli buffer and sam-
ple boiling. Anti-His and anti-O-GlcNAc RL2 antibodies were
used to detect cleavage and glycosylation of HCF3R-SEE, respec-
tively. Anti-OGT antibodies were used to determine levels of
OGT.
OGT assay
Nup62 glycosylation Purified Nup62 (500 nM) was incubated in
the presence of 500 nM OGT (wild type or mutant) in a reaction
mix supplemented with 1 mMUPD-GlcNAc and 1 mMDTT for
90min at 37°C. The reactionwas terminated by the addition of 2×
Laemmli buffer and sample boiling. Anti-O-GlcNAc RL2 was
used to assess glycosylation of Nup62, while anti-S-tag and
anti-T7 tags were used to detect total Nup62 and OGT protein
levels, respectively.
CK2 glycosylation CK2 (2500 U) purchased from New England
Biolabs was incubated with 500 nM OGT (wild type or mutant)
in 15 μL of TBS buffer supplemented with 1 mM UPD-GlcNAc
and 1 mM DTT for 90 min at 37°C. The reaction was ended by
the addition of 2× Laemmli buffer and sample boiling. Anti-
O-GlcNAc RL2 was used to assess CK2 glycosylation, while
anti-CK2 and anti-T7 tags were used to determine total CK2
and OGT protein levels, respectively.
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Sp/Rp-αS-UDP-GlcNAc cleavage and glycosylation assays
HCF-1rep1 cleavage and glycosylation and Nup62 glycosylation
assays were performed as described above but with only 0.1
mM UDP-GlcNAc or Sp/Rp-αS-UDP-GlcNAc. Synthesis of Sp/
Rp-αS-UDP-GlcNAc has been described previously (Schimpl
et al. 2012).
In vitro HCF-1–OGT-binding assay
GST-HCF-1rep1–OGT-binding assays were performed as de-
scribed previously (Bhuiyan et al. 2015). Additional details are
in the Supplemental Material.
Immunoblotting
Proteins were resolved using SDS-PAGE gels and blotted onto ni-
trocellulose membranes. The following primary antibodies were
used at 1:1000 dilution: anti-CK2α, anti-Nup62, anti-HA, and
anti-His. The following primary antibodies were used at 1:2000
dilution: anti-O-GlcNAc RL2, anti-O-GlcNAc CTD110.6, and
anti-OGT. The following primary antibodies were used at
1:5000 dilution: anti-Flag, anti-GST, and anti-Actin. The follow-
ing primary antibodies were used at 1:10,000 dilution: anti-T7
and anti-S tag. IRDye 680 donkey anti-rabbit and IRDye 800 don-
key anti-mouse antibodies were used at dilutions of 1:10,000.
Blots were imaged using the Li-Cor Odyssey infrared imaging sys-
tem (Li-Cor).
Uncleaved and cleavedHCF-1rep1 productswere quantified us-
ing ImageJ software, and cleavage efficiencies were determined as
the ratio of cleaved product band intensity over the precursor plus
cleaved product band intensity. To quantify Nup62O-GlcNAcy-
lation in Figure 3C, relative band intensities were calculated by
dividing the intensity of glycosylatedNup62 bands at the indicat-
ed time intervals by the intensity of glycosylated Nup62 after 60
min of assay.
Molecular dynamics simulations and molecular modeling
A detailed description of molecular dynamic simulations and
modeling performed in this study is in the Supplemental
Material. Molecular graphics were generated using University
of California at San Francisco Chimera (Pettersen et al. 2004).
Sequence alignment
Sequences ofOGThomologs fromHomo sapiens,Musmusculus,
Gallus gallus, Anolis carolinensis,Danio rerio,D. melanogaster,
Caenorhabditis elegans, and T. adhaerens were aligned using
ClustalW and edited and annotated with ALINE.
DetailedMaterials andMethodswith comprehensive details of
UDP release measurements, bacterial protein purification, cell
culture and transfections, in vitro binding assay, and molecular
modeling and simulations are in the Supplemental Material.
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